Humacyte moves to test bioengineered vessel in heart surgery
DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology company valued at $567 million, has announced its intention to file an Investigational New Drug (IND) application with the U.S. Food and ...
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
Plans for filing an IND was agreed with the FDA in a recent meeting –– Positive preclinical results of the small-diameter ATEV were recently ...
Humacyte announces planned IND filing in 2025 for sdATEV for CABG
Humacyte (HUMA) announced that it plans to file an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, ...
bovnews3d
Humacyte Inc (HUMA) Posted – Profit Margin Last Year—Can It Hold Up?
Humacyte Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -42.99%. The profit margin, also known as the revenue ratio or gross profit ratio, measures ...
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of “Buy” from Brokerages
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has earned a consensus recommendation of “Buy” from the eight analysts that ...
Morningstar6d
Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA
LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the ...
Yahoo Finance6d
Humacyte, Inc. (HUMA)
Humacyte announced it received full FDA approval for SYMVESS for use in adults as a a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
ETF Daily News4d
Analysts Offer Predictions for Humacyte FY2024 Earnings
Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Cantor Fitzgerald upped their FY2024 EPS estimates for Humacyte in a research note issued on Wednesday, January 15th. Cantor Fitzgerald analyst K.
The Bakersfield Californian6d
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If ...
Humacyte计划测试用于心脏手术的生物工程血管
sdATEV是一种设计用于普遍植入的生物工程人体组织，此前已在6.0毫米配置中用于血管创伤修复、血液透析的动静脉 (AV)通路和外周动脉疾病 (PAD)的研究。新的临床前试验聚焦于用于CABG的较小的3.5毫米sdATEV。2024年11月公布的为期六个月的灵长类动物临床前研究显示了令人鼓舞的结果，包括持续的血流和宿主细胞重新细胞化，减少了与原生动脉的尺寸不匹配。
人工血管技术：能否成为冠脉搭桥手术的救星？
人造血管，尤其是在冠状动脉搭桥术中的应用，能够有效降低术后并发症，同时减少手术时间和创伤。以往需要经过漫长的血管获取和修复的过程，耗费医疗资源和的人力，这无疑增加了患者的风险与痛苦。而如今，生物型人工血管的崛起或能为这些患者提供更稳定的解决方案，这也正是Humacyte和其他相关公司在激烈竞争中奋力研发的目标。
Yahoo Finance10d
Humacyte, Inc. (HUMA)
Management will also be available for DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally ...